Lewiecki EM, et al. - In this study involving postmenopausal women with osteoporosis, researchers assessed the impact of 1-year romosozumab treatment followed by 2 years of denosumab treatment on fracture risk reductions. Of 7,180 postmenopausal women enrolled in the study, 5,743 (80%) completed the 36-month study (2,851 romosozumab-to-denosumab; 2,892 placebo-to-denosumab). The participants received placebo or romosozumab once monthly for 12 months, followed by denosumab every 6 months for the next 12 months. Upon completion of the 24-month primary analysis period, eligible candidates entered the extension phase and were given denosumab for a further 12 months. The investigators found that 12 months of romosozumab led to persistent fracture reduction benefits and a gain in bone mineral density when followed by denosumab. For the treatment of osteoporosis, the sequence of romosozumab followed by denosumab might be a promising regimen.